C. Elliott

Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.

H. Linden, J. Ingle, J. St. Louis, 2014, The Lancet. Oncology.

Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor–positive breast cancer: NCIC CTG MA.27

M. Ellis, G. Sledge, J. Ingle, 2017, Cancer.

Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.

Karen A Gelmon, James N Ingle, Vered Stearns, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of adjuvant exemestane versus anastrozole on bone mineral density: Two-year results of the NCIC CTG MA.27 bone companion study.

J. Ingle, P. Goss, A. Cheung, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.

I. Tannock, K. Ding, W. Parulekar, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27

M. Ellis, K. Gelmon, G. Sledge, 2018, Journal of the National Cancer Institute.

Mammographic Breast Density Response to Aromatase Inhibition

C. Vachon, Fang-Fang Wu, J. Olson, 2013, Clinical Cancer Research.

Imaging , Diagnosis , Prognosis Mammographic Breast Density Response to Aromatase Inhibition

C. Vachon, Fang-Fang Wu, J. Olson, 2013 .

Randomized, D ouble-Blind, C ontrolled T rial o f M itoxantrone/ Prednisone a nd C lodronate V ersus M itoxantrone/Pre dnisone and P lacebo i n P atients W ith H ormone-Refracto ry P rostate Cancer a nd P ain

K. Ding, W. Parulekar, K. Chi, 2003 .

Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27

T. Whelan, K. Gelmon, J. Ingle, 2016, Breast Cancer Research and Treatment.

Treatment-Emergent Symptoms and the Risk of Breast Cancer Recurrence in the NCIC CTG MA.27 Adjuvant Aromatase Inhibitor Trial.

M. Ellis, G. Sledge, A. L. Maître, 2009 .